Paroxysmal nocturnal hemoglobinuria following alemtuzumab immunosuppressive therapy for myelodysplastic syndrome and complicated by recurrent life-threatening thrombosis despite anticoagulation: successful intervention with eculizumab and fondaparinux. [electronic resource]
Producer: 20100326Description: e85-7 p. digitalISSN:- 1873-5835
- Alemtuzumab
- Antibodies, Monoclonal -- administration & dosage
- Antibodies, Monoclonal, Humanized
- Antibodies, Neoplasm -- adverse effects
- Anticoagulants -- therapeutic use
- Fondaparinux
- Hemoglobinuria, Paroxysmal -- chemically induced
- Humans
- Immunosuppressive Agents -- adverse effects
- Male
- Middle Aged
- Myelodysplastic Syndromes -- complications
- Polypharmacy
- Polysaccharides -- administration & dosage
- Recurrence
- Thrombosis -- chemically induced
- Treatment Outcome
No physical items for this record
Publication Type: Case Reports; Letter
There are no comments on this title.
Log in to your account to post a comment.